Publications and Presentations

Therapeutic Efficacy of NSI-189 in Diabetic Mice

Authors: Karl Johe1, Alex Marquez2, Carlos Anaya2, BetelhemKifle2, NabeelMuttalib2, Corinne G. Jolivalt2, Mike Hefferan1, Nigel A. Calcutt2, 1Neuralstem, Inc; 2Department of Pathology, UCSD

Annual Meeting of the Diabetic Neuropathy Study Group of the EASD (European Association for the Study of Diabetes), held in Bucharest, Romania.

A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study of NSI-189 Phosphate, a Neurogenic Compound, in Depressed Patients

Authors: M Fava, K Johe, L Ereshefsky, L G Gertsik, B A English, J A Bilello, L M Thurmond, J Johnstone, B C Dickerson, N Makris, B B Hoeppner, M Flynn, D Mischoulon, G Kinrys, and M P Freeman. Massachusetts General Hospital, Clinical Trials and Network Institute; Harvard Medical School, Department of Psychiatry; Neuralstem, Inc., PAREXEL International, California Clinical Trials Medical Group, Ridge Diagnostics, Q-Metrx, Inc., Center for Morphometric Analysis, Massachusetts General Hospital

Molecular Psychiatry, Article first published online: December 8, 2015.

Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease

Authors: Lisa M. McGinley, Osama N. Kashlan, Kevin S. Chen, Carey Backus, Crystal Pacut, Stacey A. Sakowski, Karl Johe, Eva L. Feldman; Department of Neurology, University of Michigan (U-M), Department of Neurosurgery, U-M, A. Alfred Taubman Biomedical Research Institute, U-M, Neuralstem, Inc.

International Society for Stem Cell Research (ISSCR) Annual Meeting, Stockholm, Sweden, Poster presented June 25, 2015.

Biomarker Profiling of NSI-189 Phosphate, a Neurogenic Compound, in Patients with Major Depressive Disorder (MDD) during a Phase Ib Randomized Double-Blind, Placebo-Controlled Trial

Authors: J. A. Bilello, X. Feng, L.M. Thurmond, L. Gertsik, B.A. English, L. Ereshefsky. M. Fava, B. Hoeppner, M. Flynn, D. Mischoulon, G. Kinrys, M. Freeman, and K. Johe. Ridge Diagnostics, San Diego, CA; California Clinical Trials Medical Group, Glendale, CA; PAREXEL International, Glendale, CA. Harvard Medical School, Clinical Trials Network & Institute (CTNI), Massachusetts General Hospital, Boston, MA; Neuralstem, Inc., Germantown, MD

CNS Summit, Poster presented November 14, 2014.

Analysis of graft survival in a trial of stem cell transplant in ALS

Authors: Tezeta Tadesse, Marla Gearing, David Senitzer, Debra Saxe, Daniel J. Brat, Robert Bray, Howard Gebel, Charles Hill, Nicholas Boulis, Jonathan Riley, Eva Feldman, Karl Johe, Thomas Hazel, Meraida Polak, Jane Bordeau, Thais Federici and Jonathan D. Glass

Annals of Clinical and Translational Neurology, Article first published online: October 22, 2014.

Effects of NSI-189, a neurogenic compound, on quantitative electroencephalography (qEEG) in patients with major depressive disorder (MDD) during a phase 1b randomized, double-blind, placebo controlled, multiple ascending dose study

Authors: Brett English, PharmD, PhD, Jack Johnstone, PhD, Karl Johe, PhD, Lev Gertsik, MD, Molly Sherman, Maurizio Fava, MD Larry Ereshefsky, PharmD

The International College of Neuropsychopharmacology (CINP), Abstract posted June 17, 2014, in advance of presentation at 29th CINP World Congress of Neuropsychopharmacology: June 24, 2014.

A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study Evaluating the Effects of NSI-189 Phosphate, a Neurogenic Compound, in Patients with Major Depressive Disorder (MDD)

Authors: Maurizio Fava, MD, Karl Johe, PhD, Lev G. Gertsik, MD, Larry Ereshefsky PharmD, Bettina Hoeppner, PhD, Martina Flynn, David Mischoulon, MD, PhD, Gustavo Kinrys, MD, and Marlene Freeman, MD

American Society of Clinical Psychopharmacology (formerly NCDEU), Abstract posted May 23, 2014, in advance of oral presentation at ASCP Annual Meeting: June 17, 2014.